Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis - Wikidata - awgldk - TriplyDB

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

http://www.wikidata.org/entity/Q28207601

about

sameAs

Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis Tuberculosis presenting as immune thrombocytopenic purpura Factors influencing quality of life in patients with active tuberculosis Integrated therapy for HIV and tuberculosis Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1 Meta-Analysis-Based Preliminary Exploration of the Connection between ATDILI and Schizophrenia by GSTM1/T1 Gene Polymorphisms Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model The impact of smoking on adherence to treatment for latent tuberculosis infection Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection.Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand.Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea Identification of Mycobacterium tuberculosis clinical isolates in Bangladesh by a species distinguishable multiplex PCR.Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).National strategy for the integration of pharmacovigilance in the Moroccan TB Control Program Antitubercular therapy in patients with cirrhosis: challenges and options Cutaneous leukocytoclastic vasculitis due to anti-tuberculosis medications, rifampin and pyrazinamide.The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study Hepatic expression profiles in retroviral infection: relevance to drug hypersensitivity risk.Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Pharmacovigilance and moroccan tuberculosis public program: current situation Clinical treatment outcomes of tuberculosis treated with the basic regimen recommended by the Brazilian National Ministry of Health using fixed-dose combination tablets in the greater metropolitan area of Goiânia, Brazil The changing epidemiology of tuberculosis in a Spanish tertiary hospital (1995-2013)Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol)Intuitive weights of harm for therapeutic decision making in smear-negative pulmonary Tuberculosis: an interview study of physicians in India, Pakistan and Bangladesh.Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients.Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis

P2860

Q24246070-043AF810-7FE0-46F8-9FA5-573E2BF64676 Q24791974-69657F96-60F1-4AD7-A384-1BB667DE1AF8 Q24792888-3D566440-D3BD-4F8A-989C-66EA56FFFD07 Q26749428-FFDDAD50-63FA-4A95-8313-62EA00838DB0 Q26782448-E8335CDF-E9BA-474D-B8B3-17D1F82F8FFA Q28082718-F88E61DB-B66A-458F-BA1C-31E3118C5AB9 Q28391941-003025BE-C074-4CE3-B43E-9E65EC863CFD Q28472348-D24C61BB-3A28-4BB8-9AC1-CF3DC1866877 Q28476241-D4B17BFB-8BF4-40F7-ABC1-BF1A2C96F559 Q28478014-225D536A-AB6A-46D4-850E-EC67255C34D2 Q28478173-956D7B12-B832-4534-9472-8074151F1526 Q28478918-99350610-B13B-478B-B260-709E6E7B5202 Q28486869-B28B089E-FB4B-4F37-95E2-995FB0D42F84 Q28487731-BA7B37D1-D299-455B-AA1F-E70DFA75407D Q28533626-648000C4-64D7-4345-B412-818F6C55D58F Q28537807-53B87286-FDFB-4C85-9F73-05CE1DDB5113 Q28539060-7E90C2E5-F922-43CF-B579-0C9073467CFE Q28547892-68DB878B-B53D-492A-975C-12DBD39062CC Q28550148-2C031318-2967-4ECF-AE45-33E4164B3FFD Q30379233-4BB3B830-AC26-4253-A28D-9070A3D67DA4 Q33236454-8473A25A-644A-4F55-8D3C-3B92A9F16D80 Q33254111-E6A67B2A-19E2-4324-A2D4-DBD4C89A6D8D Q33353055-86319B42-AB05-4A23-9BBD-B68FC20EAEB3 Q33361748-14C09011-6230-401A-A977-074677532191 Q33567352-ABD9FD24-5D0D-47C7-B59C-9F5765E0DB62 Q33578429-5BEE779A-4BFC-45F1-872D-2E4A14C587A0 Q33584259-AD2434F9-8503-434A-91C8-5CC5740CFCE5 Q33585789-1939A7CD-5CD8-439B-B070-0F9D7B638DC4 Q33626827-3F360023-963F-452E-A52C-704C1563E347 Q33701325-F5687432-AD35-4E21-BE6D-3EDFF5D64A25 Q33758612-B354D1A0-E8F5-49B7-9ACF-CE6434773033 Q33777950-9D2C51F4-583E-4E50-B699-ACF00BAC3DBC Q33810290-9630EEE3-1478-4D4B-85AF-1C419F9B0DDB Q33820801-84BDE42C-AC2F-48B8-9FCC-938D1CA51352 Q33823893-86D471D6-5386-4EE4-A05C-66CC145B1567 Q33879669-E680FB2F-6758-4744-95D4-0612C6146BA7 Q33901424-4674B9B0-5702-4C67-AD1B-2DD09C73A9F9 Q34021616-D3F7C1C5-FC9F-4247-8CF2-299EA2E184F4 Q34145133-C308CEB6-8CDE-433A-AF74-E955E4F306C0 Q34146085-37F3A825-7268-4FCD-8091-557EC9C01176

P2860

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

http://www.wikidata.org/entity/Q28207601

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Incidence of serious side effe ...... reated for active tuberculosis

@ast

Incidence of serious side effe ...... reated for active tuberculosis

@en

Incidence of serious side effe ...... reated for active tuberculosis

@nl

type

label

Incidence of serious side effe ...... reated for active tuberculosis

@ast

Incidence of serious side effe ...... reated for active tuberculosis

@en

Incidence of serious side effe ...... reated for active tuberculosis

@nl

prefLabel

Incidence of serious side effe ...... reated for active tuberculosis

@ast

Incidence of serious side effe ...... reated for active tuberculosis

@en

Incidence of serious side effe ...... reated for active tuberculosis

@nl

P1433

Q28207601-33822929-C8B3-4795-AAEA-8BFEC516C83B

P1476

Q28207601-57F583D6-BD63-4B7A-823A-90D21F5EB88E

P2093

Q28207601-6D966028-F582-4DB7-9B6E-5941038DABB3

Q28207601-98899F68-94F3-49C6-84F7-EB7456554397

Q28207601-A042708D-D4DF-4668-A3AE-BD1916C56C4C

Q28207601-EBCDC2FF-D727-4AEF-B20B-C7817C92FFDF

Q28207601-FAA550F5-B61F-4620-99F6-1663F8A1CD87

P2860

Q28207601-00CD3A37-188C-4092-87C4-6643F6A9E20A

Q28207601-0A79822D-2A1C-442A-A745-ABF2BA972802

Q28207601-17F920BD-3139-497E-9A93-BC3F84CB4B62

Q28207601-27210AD8-6E7F-4C66-83F0-3A99EF7767A8

Q28207601-356E35FE-EAE9-4F77-A80A-4E10822E63F3

Q28207601-361E9395-5208-4289-9A05-FC2B884B7203

Q28207601-4EA3D30F-9CBD-4CE9-8200-814348B14629

Q28207601-68D502AE-BD96-41C1-9EBE-342CD404A4AF

Q28207601-8653D436-3DC0-417B-9F27-54E8625F012B

Q28207601-8DBD7498-4155-4A09-A310-671F21C5E010

P304

Q28207601-04536ABE-4AB1-47C4-9B6B-046902D05FC2

P31

Q28207601-8F61FBBA-CC2A-4777-8F07-FC0D955C8E58

P3181

Q28207601-56DA755D-9EA5-4BB4-9B2A-465CCBACA2F4

P356

Q28207601-286C708E-E5B5-43BA-A072-FEFF50831FD9

P407

Q28207601-3E3EA3AD-9550-49C9-B1AC-085FC86E897A

P433

Q28207601-02ABDF22-3DCD-4172-8F40-D01B18FCC696

P478

Q28207601-94AD6CBC-A08B-4C4D-9D78-8E4165D2582F

P50

Q28207601-22FBFE72-8160-4379-8AED-A81753C69D09

P577

Q28207601-40F7B820-EEFF-4E77-993F-C35CDCEF001F

P698

Q28207601-BC48FF88-235F-4638-9929-B7AC700E5D32

P921

Q28207601-46B9A9B4-9CED-46B5-8810-D2224820B62F

Q28207601-F030F8EC-BC2F-4010-B614-9E0E23E068B4

P3181

P356

RCCM.200206-626OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Incidence of serious side effe ...... reated for active tuberculosis

@en

P2093

Chantal Valiquette

http://www.w3.org/2001/XMLSchema#string

Daphne Yee

http://www.w3.org/2001/XMLSchema#string

Isabelle Parisien

http://www.w3.org/2001/XMLSchema#string

Isabelle Rocher

http://www.w3.org/2001/XMLSchema#string

Marthe Pelletier

http://www.w3.org/2001/XMLSchema#string

P2860

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

Frequency and type of reactions to antituberculosis drugs: observations in routine treatment.

Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.

Toxic hepatitis with isoniazid and rifampin. A meta-analysis.

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Liver injury during antituberculosis treatment: an 11-year study.

Isoniazid-associated hepatitis. Report of an outbreak.

Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

P304

1472-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

909398

http://www.w3.org/2001/XMLSchema#string

P356

10.1164/RCCM.200206-626OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12569078

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde